Broadened rollout of inVue Dx FNA with full availability planned by end-2026
Cancer Dx expansion into a multi-cancer panel with mast cell tumor detection in late Q3 2026
Field commercial expansion across four international countries and targeted U.S. additions in second-half 2026
Raised FY2026 revenue outlook on stronger CAG Diagnostics recurring revenue momentum
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for IDEXX Laboratories, Inc. and 4,900+ companies.